A treatment protocol for botulinum toxin injections in the treatment of pachyonychia congenita‐associated keratoderma
- 25 May 2019
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 182 (3) , 671-677
Abstract
Background Severely debilitating plantar keratoderma pain is the most distressing clinical feature of pachyonychia congenita (PC). Several earlier publications reported therapeutic success with botulinum toxin (Btx) plantar injections. Objectives To describe our 4‐year experience during which we administered a total of 30 plantar Btx injections to five PC patients following an optimized protocol. Methods Five patients with PC (age 21‐54 years) who were treated at our medical center from 4/2015 to 6/2018 were included in the study. After an ultrasound‐guided nerve block performed by an anesthesiologist, the patients received plantar intradermal injections of Btx A. To ascertain the effect of the treatment, we used a dedicated quality‐of‐life questionnaire for PC patients (PCQoL) and asked the patients to evaluate the intensity of eight parameters pertaining to their symptoms at baseline and before every treatment session. At study closure, patients were asked to evaluate the maximal improvement in the same eight parameters throughout the study period. Results All patients demonstrated a decrease in PCQoL scores during the follow‐up period. All patients showed a significant improvement in PCQoL after the first treatment session and at the last evaluation (P = 0.043). The best improvement scores concerned morning feet burning and long‐distance walking (> 500 m). The scores were significantly lower if the intervals between Btx injections were <100 days. Conclusions Btx treatment of PC‐associated keratoderma following an optimized protocol leads to a major change in patients’ quality of life.Keywords
This publication has 18 references indexed in Scilit:
- Comparative Study of High-Resolution Multifrequency Ultrasound of the Plantar Skin in Patients with Various Types of Hereditary Palmoplantar KeratodermaDermatology, 2013
- A review of the clinical phenotype of 254 patients with genetically confirmed pachyonychia congenitaJournal of the American Academy of Dermatology, 2012
- Keratin disorders: from gene to therapyHuman Molecular Genetics, 2011
- Statins Downregulate K6a Promoter Activity: A Possible Therapeutic Avenue for Pachyonychia CongenitaJournal of Investigative Dermatology, 2011
- The Phenotypic and Molecular Genetic Features of Pachyonychia CongenitaJournal of Investigative Dermatology, 2011
- Botulinum toxin in the treatment of sweat-worsened foot problems in patients with epidermolysis bullosa simplex and pachyonychia congenitaBritish Journal of Dermatology, 2010
- Subcutaneous Botulinum toxin type A reduces capsaicin-induced trigeminal pain and vasomotor reactions in human skinPain, 2009
- Botulinum toxin type A inhibits sensory neuropeptide release in rat bladder models of acute injury and chronic inflammationBJU International, 2008
- Treatment of pachyonychia congenita with plantar injections of botulinum toxinBritish Journal of Dermatology, 2006
- Botulinum Toxin A reduces neurogenic flare but has almost no effect on pain and hyperalgesia in human skinJournal of Neurology, 2003